SAN MATEO, Calif., October 8, 2025 — Vivace Therapeutics, Inc., a biotechnology company pioneering small molecule cancer therapies that target the Hippo signaling pathway, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VT3989, the company’s first-in-class TEAD (transcriptional enhanced associate domain) autopalmitoylation inhibitor, for the treatment of unresectable malignant pleural and non-pleural mesothelioma in patients whose disease has progressed following prior immune checkpoint inhibitor therapy and platinum-based chemotherapy.
Science SignificanceAVB-114
The Hippo signaling pathway has emerged as a crucial regulator of cell growth, apoptosis, and organ size control, with aberrant signaling linked to the development of numerous solid tumors, including mesothelioma, renal cell carcinoma, and cholangiocarcinoma. VT3989 represents the first and only clinical-stage TEAD autopalmitoylation inhibitor designed to block this pathway by preventing lipid modification of TEAD proteins, thereby disrupting YAP/TAZ-mediated transcriptional activation that drives oncogenesis. In an ongoing Phase 1 clinical study, more than 200 patients with refractory metastatic solid tumors, including mesothelioma, have received VT3989. The compound has shown encouraging early signs of clinical efficacy and a favorable safety profile, supporting its best-in-class potential. Vivace’s achievement is particularly notable as no other TEAD inhibitors have demonstrated this level of translational validation, positioning VT3989 as a front-runner in a novel mechanistic space within oncology drug discovery. The scientific implications extend beyond mesothelioma, as inhibition of TEAD autopalmitoylation may offer a new therapeutic strategy for a broad range of NF2-mutated cancers, potentially reshaping targeted cancer therapy paradigms.
Regulatory Significance
The FDA Fast Track Designation highlights VT3989’s potential to address an urgent unmet need in mesothelioma, a cancer with limited treatment options and a median survival of less than one year after relapse. This designation allows more frequent FDA interactions, rolling review, and potential eligibility for priority review and accelerated approval, expediting the clinical development and regulatory pathway for VT3989.We are pleased to receive Fast Track Designation from the FDA for VT3989 in this patient population, which is in desperate need of new and effective therapeutic options, said Sofie Qiao, Ph.D., President and CEO of Vivace Therapeutics. She emphasized that this milestone “represents another important step in our ongoing development of VT3989 and offers key advantages as we continue toward potential commercialization of this first-in-class and best-in-class therapy. The Fast Track status underscores the regulatory community’s growing confidence in the Hippo pathway as a viable therapeutic target. It also positions Vivace to accelerate pivotal trials, potentially shortening time to market for a treatment that could meaningfully extend survival in refractory mesothelioma.
Business Significance
Advertisement
Founded in the San Francisco Bay Area, Vivace Therapeutics has raised $105 million to date and has established itself as a leading innovator in Hippo pathway drug discovery. The Fast Track Designation confers a significant competitive advantage and is likely to enhance investor confidence, opening opportunities for new strategic partnerships or funding rounds to support Phase 2/3 clinical development. The designation also strengthens Vivace’s positioning in the oncology innovation ecosystem, where large pharmaceutical companies are actively seeking collaborations around first-in-class mechanisms. Given the limited number of validated TEAD inhibitors globally, Vivace now holds a potentially exclusive first-mover advantage in developing small-molecule modulators targeting this pathway. This development further amplifies the company’s strategic value as the oncology field shifts toward precision-driven molecular therapies that address rare and resistant cancer populations.
Patients’ Significance
Mesothelioma remains a devastating and largely incurable disease, often caused by asbestos exposure, with limited benefit from existing treatments such as chemotherapy and immunotherapy. Patients who relapse after frontline therapy face few effective options. VT3989 offers hope to a patient population with minimal therapeutic recourse, introducing a mechanism that directly interrupts cancer cell proliferation at the transcriptional level. The early clinical data suggest that VT3989 may achieve durable disease control with manageable side effects, representing a potential breakthrough in quality of life and survival outcomes for individuals battling this aggressive malignancy. As a first-in-class targeted therapy, VT3989 could eventually be developed for combination use or expanded indications in other TEAD-activated tumor types, further benefiting patients across multiple cancers.
Policy Significance
The FDA’s decision aligns with a broader U.S. policy focus on accelerating access to innovative oncology drugs, particularly those for rare and hard-to-treat cancers. Fast Track programs are part of the FDA’s ongoing efforts to modernize regulatory pathways and support precision oncology innovations that can rapidly transition from discovery to patient care. This designation exemplifies how science-driven small biotech firms are shaping national health policy outcomes, leveraging federal mechanisms to deliver novel therapies faster. It also reinforces the value of the FDA’s flexible review frameworks in enabling breakthroughs from early-stage companies like Vivace Therapeutics.
Transaction Highlights
Vivace Therapeutics’ lead candidate, VT3989, has received Fast Track Designation from the U.S. FDA for treating unresectable malignant pleural and non-pleural mesothelioma that has progressed after immune checkpoint inhibitor therapy and platinum-based chemotherapy. This designation provides key regulatory advantages, including more frequent FDA interactions, rolling review, and eligibility for accelerated approval, expediting the path toward commercialization. VT3989 is a first-in-class TEAD (transcriptional enhanced associate domain) autopalmitoylation inhibitor targeting the Hippo signaling pathway, a critical driver of tumor survival. The compound has been evaluated in over 200 patients in an ongoing Phase 1 trial (NCT04665206) and has shown a favorable safety profile with early clinical efficacy, reinforcing its best-in-class potential. The Fast Track status validates Vivace’s innovative approach to TEAD inhibition and highlights the FDA’s recognition of its potential to address high unmet medical need in mesothelioma. With $105 million raised to date, Vivace is well positioned to advance VT3989 into late-stage trials, while exploring additional cancer indications linked to Hippo pathway dysregulation. This milestone strengthens Vivace’s position as a leader in precision oncology, combining scientific novelty, regulatory momentum, and a clear path toward addressing critical treatment gaps in aggressive cancers.
Source: Vivace Therapeutics, Inc. Press Release
